Combining the BRAFi dabrafenib (TAFINLAR®) and the MEKi trametinib (MEKINIST®) is an effective dual BRAF/MEK inhibition for cancer therapy, and the U.S. Food and Drug Administration (FDA) has approved these drugs for mono- and combination-therapy (Figure 1). This evidence concerns the gene MAP2K7 and cancer.